[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8, Issue 3 (Int J Mol Cell Med 2019) ::
Int J Mol Cell Med 2019, 8(3): 200-210 Back to browse issues page
Inhibitor of Interleukin-1 Receptor-Associated Kinases 1/4, Can Increase the Sensitivity of Breast Cancer Cells to Methotrexate
Samaneh Rahemi1, Seyed Noureddin Nematollahi-Mahani2, Athena Rajaie1, Hossein Fallah 3
1- Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
2- Department of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
3- Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. , hf59ma@gmail.com
Abstract:   (2852 Views)
Breast cancer is the most common type of cancer among women. Chemotherapy is one of the main methods of breast cancer treatment, but this method is increasingly affected due to drug resistance. One of the newly discovered factors associated with drug resistance in cancer cells is interleukin receptor-associated kinase 1 (IRAK1). The aim of this study was to investigate the relationship between IRAK1 inhibition and sensitivity to methotrexate (MTX). Effects of various concentrations of MTX and constant concentration (1μg/ml) of IRAK1/4 inhibitor was examined on MCF-7, BT-20, BT-549, MB-468 cell lines. Cell viability was examined by water-soluble tetrazole -1, and cell apoptosis by flow cytometry. The expression of IRAK1 and BCRP genes was also assessed by the real-time PCR method. IRAK1 inhibitor decreased IC50 in all examined cell lines, but the most prominent effect was observed in MB-468.  72 h incubation of cell lines with IRAK inhibitor and MTX, significantly increased the annexin-V and annexin-V/7AAD positive cells, suggesting an apoptotic effect of IRAK on all examined breast cancer cell lines. RT-qPCR test results showed that the IRAK inhibitor had no effect on the expression of BCRP at any time. Our results showed that the IRAK inhibitor can increase the chemosensitivity of breast cancer cell lines without effect on BCRP mRNA expression. IRAK inhibitor in combination with MTX can induce apoptosis in breast cancer cell lines.
Keywords: Drug Resistance, Breast Cancer, Methotrexate, IRAK inhibition
Full-Text [PDF 475 kb]   (792 Downloads)    
Type of Study: Original Article | Subject: Cancer
Received: 2019/06/21 | Accepted: 2020/01/10 | Published: 2020/04/26
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahemi S, Nematollahi-Mahani S N, Rajaie A, Fallah H. Inhibitor of Interleukin-1 Receptor-Associated Kinases 1/4, Can Increase the Sensitivity of Breast Cancer Cells to Methotrexate. Int J Mol Cell Med. 2019; 8 (3) :200-210
URL: http://ijmcmed.org/article-1-1110-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 8, Issue 3 (Int J Mol Cell Med 2019) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.06 seconds with 30 queries by YEKTAWEB 4419